Additionally, Ibrutinib-resistant primary CLL cell growth was inhibited by Cerdulatinib, and these anti-tumor effects were proposed to be linked to inhibition of BCR, IL-4/Jak1/Jak3/Stat6 and IL-6/Jak1/Jak2/Stat3 signaling [196]. Here, JAK1 is linked to B-cell chronic lymphocytic leukemia.